SILVER SPRING, Md. — The Food and Drug Administration on Tuesday advised consumers not to purchase or use “MAXILOSS Weight Advanced” — a product promoted and sold for weight loss on various web sites, including DreamLifeWeightLoss.com, and in some retail stores.

FDA laboratory analysis confirmed that “MAXILOSS Weight Advanced” contains sibutramine, a controlled substance that was removed from the market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke. This product may also interact in life-threatening ways with other medications a consumer may be taking.

Consumers should stop using this product immediately and throw it away. Consumers who have experienced any negative side effects should consult a healthcare professional as soon as possible.

This notification is to inform the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals, the FDA noted. These products are typically promoted for sexual enhancement, weight loss and body-building and are often represented as being “all natural.”

Poll

Poll

SPECIAL REPORTS

Are we in the midst of a beauty revolution? Perhaps. It is no secret that the ever-changing beauty category is all about trends, but one could argue that we are embarking on an especially interesting time in beauty as technology is changing the way consumers shop and new innovations strive to break through the noise.

In this beauty report, Drug Store News takes a deeper dive into some of the leading trends that are reshaping beauty.more ...

IN THIS ISSUE

In this issue, DSN examines PricewaterhouseCoopers' "Top Health Industry Issues for 2015;" takes you on a tour of Murad, shares beauty trends and insights and delves into location-based technology and how it is revolutionizing health, retail.Click here to view the issue.